Moving Toward Bioadjuvant Approaches to Head and Neck Cancer Prevention

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2 SUPPL., 2007, Pages

  Saba, Nabil F ^a   Hammond, Anthea ^a   Shin, Dong M ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer prevention; Head and neck cancer; Natural compounds; Retinoids

Indexed keywords

BIOMARKERS; PATIENT TREATMENT; RISK ANALYSIS; TOXICITY; TUMORS; VIRUSES;

CANCER PREVENTION; NATURAL COMPOUNDS; RETINOIDS;

ONCOLOGY;

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; CELECOXIB; CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETRETINATE; FLUOROURACIL; GEFITINIB; GREEN TEA EXTRACT; INTERFERON; ISOTRETINOIN; NATURAL PRODUCT; ONCOLYTIC VIRUS; ONYX 015; PLACEBO; RETINOID; RETINOL PALMITATE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER PREVENTION; CANCER RISK; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR;

ADENOVIRIDAE; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2 INHIBITORS; ETRETINATE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOIDS; VITAMIN A;

EID: 34548378700     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.041     Document Type: Article

References (31)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 110 (1984) 564-565
4. Hong W.K., Lippman S.M., Itri L.M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323 (1990) 795-801
5. Benner S.E., Pajak T.F., and Lippman S.M. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long term follow-up. J Natl Cancer Inst 86 (1994) 140-141
6. Pastorino U., Infante M., and Maioli M. Adjuvant treatment for stage I lung cancer with high-dose vitamin A. J Clin Oncol 11 (1993) 1216-1222
7. Bolla M., Lefur R., Ton Van J., et al. Prevention of second primary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx: Results of a multicentric double-blind randomized study. Eur J Cancer 30A (1994) 767-772
8. van Zandwijk N., Dalesio O., Pastorino U., et al., for the European Organization for Research and Treatment of Cancer and the Head and Neck and Lung Cancer Cooperative Groups. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 92 (2000) 977-986
9. Lippman S.M., Lee J.J., Karp D.D., et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 93 (2001) 605-618
10. Khuri F.R., Lee J.J., Lippman S.M., et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98 (2006) 441-450
11. Freemantle S.J., Spinella M.J., and Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 22 (2003) 7305-7315
12. Petty W.J., Li N., Biddle A., et al. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 97 (2005) 1645-1651
13. Xu X.C., Ro J.Y., Lee J.S., et al. Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res 54 (1994) 3580-3587
14. Chun K.H., Benbrook D.M., Berlin K.D., et al. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res 63 (2003) 3826-3832
15. Smith W., and Saba N. Retinoids as chemoprevention for head and neck cancer: Where do we go from here?. Crit Rev Oncol Hematol 55 (2005) 143-152
16. Papadimitrakopoulou V.A., Clayman G.L., Shin D.M., et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125 (1999) 1083-1089
17. Shin D.M., Khuri F.R., Murphy B., et al. Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant phase II trial. J Clin Oncol 19 (2001) 3010-3017
18. Seixas-Silva Jr. J.A., Richards T.J., Khuri F.R., et al. Phase 2 bioadjuvant study of interferon-alpha-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: Long term follow-up. Arch Otolaryngol Head Neck Surg 131 (2005) 304-307
19. Cohen E.E., Lingen M.W., Martin L.E., et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11 (2005) 8105-8108
20. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
21. Khuri F.R., and Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 10 (2004) 4249s-4253s
22. Bertagnolli M.M. COX-2 and cancer chemoprevention: Picking up the pieces. Recent Results Cancer Res 174 (2007) 73-78
23. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
24. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
25. Choe M.S., Zhang X., Shin H.J., et al. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4 (2005) 1448-1455
26. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6 (2000) 879-885
27. Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21 (2003) 4546-4552
28. Chainani-Wu N. Diet and oral, pharyngeal, and esophageal cancer. Nutr Cancer 44 (2002) 104-126
29. Hsu S.D., Singh B.B., Lewis J.B., et al. Chemoprevention of oral cancer by green tea. Gen Dent 50 (2002) 140-146
30. Casto B.C., Kresty L.A., Kraly C.L., et al. Chemoprevention of oral cancer by black raspberries. Anticancer Res 22 (2002) 4005-4015
31. Lippman S.M. The dilemma and promise of cancer chemoprevention. [Editorial]. Nat Clin Pract Oncol 3 (2006) 523